“I was keen to go on a clinical trial. I wanted to try new cancer treatments and hopefully help future generations.”
A trial looking at xyotax for breast cancer that has spread (PH2/044)
This trial looked at a new drug called xyotax (CT 2103) for breast cancer that has spread to another part of the body. This trial was supported by Cancer Research UK.
Doctors usually use chemotherapy to treat breast cancer that has spread. One group of drugs they use are the ‘
The aims of this trial were to find out
- If xyotax is useful for treating breast cancer that has spread
- What the side effects are
Summary of results
The results of this trial are mixed. The trial team found that xyotax may be useful for people who had not had a taxane drug before. But they also found that it had some quite severe side effects.
The trial recruited 26 people, 18 people who had had taxanes before and 8 who had not.
The research team were able to analyse the results of 24 patients. They found that the cancer shrank in 4 people, and none of these 4 people had had a taxane before. It stayed the same in 14 people, and it continued to grow in 6 people. It didn’t go away completely for anyone.
The trial team had planned to recruit 60 people for this trial. But xyotax caused nerve damage (neuropathy) in some people taking part, which was sometimes severe. So they decided to stop the trial earlier than planned.
We have based this summary on information from the team who ran the trial. As far as we are aware, the information they sent us has not been reviewed independently (
How to join a clinical trial
Professor Hilary Calvert
Cancer Research UK (Centre for Drug Development)
This is Cancer Research UK trial number CRUKD/02/024.